Niagen Bioscience Inc Q1 FY2025 earnings call

• Revenue in Q1 2025 was $30.5 million, a 38% year-over-year increase. Net income was $5.1 million, and cash from operations was $7.9 million, ending the quarter with $55.6 million in cash and no debt.
• Niagen Plus (intravenous and injection Niagen) is available at nearly 600 clinics nationwide, with positive feedback on faster infusion time and minimal side effects. Partnerships with clinics at events like SoCal Wellness Summit were mentioned.
• A new composition of matter patent for nicotinamide riboside was granted in March, broadening the patent portfolio.
• Addressed market misconceptions about NAD supplementation, stating NAD can't bypass cell membranes and must use precursors like NR. Noted three quarters of higher-selling NAD supplements on Amazon failed label claims.
• FDA ruling that NMN is not a lawful dietary ingredient was affirmed, with urging for enforcement to protect consumers.

In the first quarter of 2025, Niagen Biosciences delivered total net sales of $30.5 million, a 38% increase from the same period last year. The e-commerce segment, driven by Tru Niagen, had net sales of $16.8 million, representing a 31% year-over-year increase. The ingredient business, including food grade and pharmaceutical grade Niagen, grew to $8 million, a 95% year-over-year increase. E-commerce contributed around 55.1% of total revenue, and the ingredient business contributed approximately 26.2% of total revenue.

• Raised full-year top-line growth outlook from approximately 18% to a range of 20% to 25% year-over-year, driven by momentum in e-commerce and ingredient businesses.
• Adjusted general and administrative expenses outlook to an increase of approximately $7 million to $8 million year-over-year, primarily due to share-based compensation related to performance stock grants.

• Market misconceptions about NAD supplementation methods, where NAD itself isn't effective in elevating NAD levels.
• Potential impact of evolving international trade policies on supply chain and cost structure.
• Uncertainties regarding the timing and outcomes of clinical trials, such as the Phase 3 NOPARK study for Parkinson's disease and discussions with FDA on AT.

Q: Any sense of ordering patterns for Niagen IV and BUD?

A: Launched in August, initially ran out of supply but now replenished. Some anecdotal patterns like 'Niagen Glow' and improved sleep noted, but more studies needed.

Q: Status of FDA discussions on AT and Niagen?

A: Active discussions with FDA, submitted pre IND in October, responded to comments, and progressing, with potential developments later this year.